Which has the lower trailing P/E, ACAD or CDNA?

ACAD has the lower trailing P/E: ACAD trades at 9.06 and CDNA at 33.72. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, ACAD or CDNA?

Over the past five years, ACAD grew revenue faster — ACAD at a 19.70% CAGR versus CDNA at 12.56%.

Is ACAD or CDNA more profitable?

ACAD runs the higher net margin — ACAD at 33.42% versus CDNA at 24.23%.

How have ACAD and CDNA total returns compared?

Over the past 10 years, ACAD delivered -3.53% and CDNA delivered 34.41% annualized total return. Past performance doesn't predict future results.

Acadia Pharmaceuticals Inc. (ACAD) vs CareDx, Inc (CDNA)

A side-by-side comparison of Acadia Pharmaceuticals Inc. and CareDx, Inc across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

ACAD

Acadia Pharmaceuticals Inc.

$3.44B

$20.11HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

CDNA

CareDx, Inc

$3.61B

$69.85HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT

Total return — ACAD vs CDNA

growth of $100 · dividends reinvested · last 10y

ACAD -36.8% (-4.5%/yr)CDNA +1824.2% (+34.4%/yr)CDNA compounded faster over this window

Log scale — wide-divergence pair

ACAD CDNA

ACAD vs CDNA: by the numbers

•CDNA is the larger company ($3.61B vs $3.44B market cap).
•ACAD trades at the lower trailing earnings multiple (9.06 vs 33.72 P/E), one valuation lens rather than an overall verdict.
•ACAD converts more revenue to profit (33.42% vs 24.23% net margin).
•ACAD grew revenue faster over the past five years (19.70% vs 12.56% CAGR).

Metrics side by side

Valuation

Metric	ACAD	CDNA
P/E ratio	9.06	33.72
Forward P/E	32.65	58.32
P/S ratio	3.02	7.89
P/B ratio	2.64	8.49
EV / EBITDA	31.84	209.49
FCF yield	5.06%	2.35%

Profitability

Metric	ACAD	CDNA
Gross margin	91.13%	70.58%
Operating margin	7.59%	-0.92%
Net margin	33.42%	24.23%
ROE	29.12%	26.08%
ROIC	6.25%	-0.93%

Growth (annualized)

Metric	ACAD	CDNA
Revenue CAGR (5Y)	19.70%	12.56%
Total return CAGR (5Y)	3.52%	1.33%

Frequently asked

Which has the lower trailing P/E, ACAD or CDNA?: ACAD has the lower trailing P/E: ACAD trades at 9.06 and CDNA at 33.72. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, ACAD or CDNA?: Over the past five years, ACAD grew revenue faster — ACAD at a 19.70% CAGR versus CDNA at 12.56%.
Is ACAD or CDNA more profitable?: ACAD runs the higher net margin — ACAD at 33.42% versus CDNA at 24.23%.
How have ACAD and CDNA total returns compared?: Over the past 10 years, ACAD delivered -3.53% and CDNA delivered 34.41% annualized total return. Past performance doesn't predict future results.

Go deeper

Full ACAD analysis Full CDNA analysis Interactive comparison tool

Dig into the metrics

Acadia Pharmaceuticals P/E ratio CareDx P/E ratio Acadia Pharmaceuticals ROE CareDx ROE Acadia Pharmaceuticals operating margin CareDx operating margin Acadia Pharmaceuticals revenue growth CareDx revenue growth Acadia Pharmaceuticals free cash flow CareDx free cash flow

Acadia Pharmaceuticals & CareDx appear in these rankings

Fastest Revenue Growth Stocks Highest ROE Stocks Highest FCF Yield Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.